drugset
drugset / Trial / NCT00867659

The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors

NCT00867659 ↗

Completed 20 enrolled Virginia Center for Reproductive Medicine
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This pilot study aims to address whether the prophylactic use of Cetrorelix Acetate after a long gonadotropin-releasing hormone (GnRH) agonist protocol post-hCG (human chorionic gonadotropin) administration can significantly reduce the incidence of OHSS in oocyte donors.

Timeline

Start
2009-03
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetrorelix Other / unclassified 3 mg —

Indications

ovarian hyperstimulation syndrome